BSE Live
Apr 07, 16:01Prev. Close
4839.75
Open Price
4800.30
Bid Price (Qty.)
4775.35 (1)
Offer Price (Qty.)
4796.00 (1)
NSE Live
Apr 07, 15:59Prev. Close
4839.90
Open Price
4839.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Pfizer (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 642.49 | 659.91 | 547.91 | 516.83 | 470.42 | |
| Net CashFlow From Operating Activities | 323.18 | 97.81 | 331.80 | 328.82 | 345.48 | |
| Net Cash Used In Investing Activities | 1,530.32 | 35.12 | -238.30 | -249.64 | -700.87 | |
| Net Cash Used From Financing Activities | -163.52 | -109.85 | -110.35 | -82.59 | -61.88 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | -0.05 | -0.08 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 1,689.98 | 23.08 | -16.85 | -3.46 | -417.35 | |
| Cash And Cash Equivalents Begin of Year | 73.81 | 50.73 | 67.58 | 71.05 | 488.40 | |
| Cash And Cash Equivalents End Of Year | 1,763.79 | 73.81 | 50.73 | 67.59 | 71.05 |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
08.04.2026
08.04.2026
07.04.2026
Kiran Mazumdar‑Shaw calls for new IPO rules to unlock India’s innovation potential in life sciences
07.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth